Targets Pharmaceutical R&D Market Rapid, Non-Destructive Analysis Contributes to Quality, Productivity Gains
http://www.advantest.com/aac/News/090111.html
TOKYO, Japan, September 1, 2011 - Advantest Corporation (TSE: 6857, NYSE: ATE) today announced that it has developed a new desktop spectroscopic and imaging system for the pharmaceutical R&D market, the TAS7500, which utilizes terahertz waves1 to perform non-destructive sample analysis.
The TAS7500 relies on a proprietary method developed by Advantest to achieve rapid, non-destructive imaging and analysis of pharmaceutical samples in the liquid or solid state. Crystalline qualities, the characteristics of constituents, and even the thickness, density, and internal structure of pill coating - formerly impossible to analyze non-destructively - may be analyzed and visually rendered in two or three dimensions. The system offers lower costs and higher efficiency at all stages of drug development from lab research to process scale-up. According to Advantest, the TAS7500 is poised to contribute to the new approach to pharmaceutical R&D, which is based on intelligent risk management, and incorporates the ICH2 guidelines that are being adopted by an increasing number of firms.
Advantest will exhibit the TAS7500 at the 49th JAIMA EXPO 2011 / 34th SIS 20113, scheduled to take place on September 7th, Wednesday through September 9th, Friday 2011 at Makuhari Messe, near Tokyo.
No comments:
Post a Comment